Established Cardiovascular Disease: What Counts as Treatment Failure

Defining Established Cardiovascular Disease

Established cardiovascular disease (CVD) is not a single diagnosis. It is a clinical category that includes a prior myocardial infarction (MI), ischemic stroke or transient ischemic attack, peripheral arterial disease (PAD), or documented symptomatic coronary artery disease confirmed by angiography or functional testing. Patients carrying any of these diagnoses are classified as very-high risk by the 2018 ACC/AHA Cholesterol Guideline and require the most aggressive preventive targets available. [1]

Why the Distinction Matters for Treatment Failure

The threshold for "failure" is calibrated differently in established CVD than in primary prevention. A 45-year-old with no prior events and an LDL-C of 85 mg/dL might be acceptable on a moderate statin. The same LDL-C in a 62-year-old three years post-MI represents active treatment failure. The 2019 ESC/EAS dyslipidaemia guidelines set an LDL-C target of <55 mg/dL for very-high-risk patients and explicitly recommend escalation if that target is not reached within three months. [2]

The Patient Population in Numbers

Approximately 18.2 million U.S. Adults have coronary artery disease alone, according to the CDC. [3] Roughly 50 to 60 percent of secondary-prevention patients do not achieve their LDL-C targets on statin monotherapy, a gap documented in the EUROASPIRE V survey across 27 European countries. [4] That gap is the single most common form of treatment failure in this population.

What the Major Guidelines Define as Treatment Failure

Treatment failure in established CVD does not have one universal definition, but consensus across ACC/AHA, ESC/EAS, and AACE converges on four distinct failure modes: residual lipid risk, recurrent atherosclerotic events, medication intolerance, and functional/hemodynamic decline.

Failure Mode 1: Persistent Elevated LDL-C Despite Optimized Statin Therapy

The 2018 ACC/AHA guideline recommends high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg daily) as the foundation for all established CVD patients. [1] If LDL-C remains at or above 70 mg/dL after three months on that regimen, the guideline calls for adding ezetimibe 10 mg daily. If LDL-C still stays at or above 70 mg/dL on statin plus ezetimibe, a PCSK9 inhibitor (evolocumab or alirocumab) is a Class IIa recommendation.

The IMPROVE-IT trial (N=18,144) showed ezetimibe added to simvastatin reduced the composite CV endpoint by a further 6.4% relative reduction over 7 years compared with simvastatin alone (P<0.016), confirming that residual LDL-C above target is a treatable failure mode, not just a statistical inconvenience. [5]

PCSK9 inhibitors close the gap more aggressively. In FOURIER (N=27,564), evolocumab lowered LDL-C by 59% from baseline and reduced the primary composite endpoint (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% over a median 2.2 years (P<0.001). [6]

Failure Mode 2: Recurrent Major Adverse Cardiovascular Events (MACE) on Therapy

A recurrent non-fatal MI, non-fatal stroke, or cardiovascular death while a patient is on guideline-directed medical therapy (GDMT) is the clearest signal that current treatment is insufficient. Recurrence rates remain high: roughly 1 in 5 patients with a prior MI will experience a second MI within five years even in contemporary clinical practice. [7]

Recurrent MACE triggers a full medication review. Clinicians must confirm statin dose and adherence, assess platelet inhibition (single vs. Dual antiplatelet therapy), and screen for uncontrolled hypertension, diabetes, and obesity. Each of these factors is an independent, modifiable driver of residual risk.

Failure Mode 3: Statin Intolerance After Two Trials

Statin-associated muscle symptoms (SAMS) affect an estimated 7 to 29 percent of patients in observational registries. [8] The ACC/AHA defines statin intolerance as the inability to tolerate at least two different statins, including one trial at the lowest approved starting dose. The preferred approach before labeling a patient statin-intolerant is:

1. Reduce dose and retry the same statin.
2. Switch to a different statin (e.g., from atorvastatin to rosuvastatin or pravastatin).
3. Consider alternate-day dosing for rosuvastatin or fluvastatin XL.

If two separate trials fail, the patient qualifies for non-statin therapy (ezetimibe, bempedoic acid, PCSK9 inhibitor) as primary LDL-lowering. The CLEAR Outcomes trial (N=13,970) demonstrated bempedoic acid reduced MACE by 13% vs. Placebo (P=0.004) in statin-intolerant patients with or at high risk of CVD, providing a direct treatment option for this failure mode. [9]

Failure Mode 4: Progressive Heart Failure Despite GDMT

For patients whose established CVD includes heart failure with reduced ejection fraction (HFrEF), treatment failure is defined by the 2022 AHA/ACC/HFSA Heart Failure Guideline as: ejection fraction <40% persisting after 3 months on maximally tolerated ACE inhibitor or ARB (or ARNI), beta-blocker, and mineralocorticoid receptor antagonist. [10] Persistent NYHA Class III or IV symptoms, two or more hospitalizations for decompensated heart failure within 12 months, or ongoing NT-proBNP elevation above 1,000 pg/mL each represent distinct escalation triggers.

The DAPA-HF trial (N=4,744) showed dapagliflozin reduced the composite of worsening HF or CV death by 26% (P<0.001) compared with placebo in HFrEF patients regardless of diabetes status, establishing SGLT2 inhibitors as a mandatory fourth pillar of HFrEF therapy when patients fail the traditional three-drug regimen. [11]

Residual Cardiovascular Risk Beyond LDL-C

LDL-C is not the only biomarker that signals treatment failure. Residual risk persists through several other pathways even when LDL-C is on target.

Elevated Triglycerides and Low HDL-C

The REDUCE-IT trial (N=8,179) showed icosapent ethyl 4 g daily reduced MACE by 25% (P<0.001) in patients with triglycerides 135 to 499 mg/dL on statin therapy, a level many clinicians had previously accepted as "controlled enough." [12] Triglycerides above 150 mg/dL on statin therapy now represent a distinct residual risk failure mode, particularly for patients with established CVD and concomitant hypertriglyceridemia.

Elevated High-Sensitivity CRP

Persistent inflammation, measured by high-sensitivity CRP (hsCRP) above 2.0 mg/L despite statin therapy, independently predicts recurrent events. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg daily cut hsCRP by 37% and reduced MACE by 44% (P<0.00001) in patients with elevated hsCRP and normal LDL-C. [13] When a patient's hsCRP remains elevated despite a high-intensity statin, that signal merits reassessment of lifestyle factors, inflammatory comorbidities, and potentially colchicine therapy. The LoDoCo2 trial (N=5,522) found colchicine 0.5 mg daily reduced MACE by 31% in stable coronary disease (P<0.001). [14]

Uncontrolled Blood Pressure

A systolic blood pressure above 130 mmHg on two or more antihypertensives constitutes treatment failure for blood pressure in established CVD. The 2017 ACC/AHA Hypertension Guideline classifies 130 to 139 mmHg as Stage 1 hypertension and recommends pharmacotherapy alongside lifestyle modification for CVD patients. [15] Persistent hypertension is both a treatment failure marker and a driver of ongoing MACE risk.

Obesity and Overweight as a Distinct Treatment-Failure Driver

Excess body weight is not just a comorbidity. It sustains cardiovascular risk through insulin resistance, dyslipidemia, hypertension, and systemic inflammation even when individual risk factors appear treated. The SELECT trial redefined how clinicians should think about weight in established CVD.

The SELECT Trial: Semaglutide in CVD Without Diabetes

SELECT (N=17,604) enrolled adults aged 45 or older with established CVD (prior MI, stroke, or symptomatic PAD), a BMI of 27 or higher, and no diabetes at baseline. Participants received semaglutide 2.4 mg subcutaneous once weekly or placebo on top of standard care. At a mean follow-up of 39.8 months, semaglutide reduced the primary three-point MACE composite (CV death, non-fatal MI, non-fatal stroke) by 20% (hazard ratio 0.80; 95% CI 0.72 to 0.90; P<0.001). [16]

This is the first trial to show that a weight-management medication independently reduces hard cardiovascular endpoints in people without diabetes. The absolute risk reduction of 1.5 percentage points (from 8.0% to 6.5%) over roughly 3.3 years translates to a number needed to treat of approximately 67.

The HealthRX clinical team uses the SELECT result to define a new treatment-failure criterion for established CVD patients who remain overweight or obese: BMI ≥27 with established CVD, off-target weight despite structured lifestyle intervention for 6 months, and no current GLP-1 receptor agonist prescription. These patients meet criteria for semaglutide escalation regardless of whether their lipid and blood pressure targets are formally met.

Why Weight Loss Alone Does Not Explain the Benefit

Weight loss in the semaglutide arm of SELECT averaged 9.4% at 104 weeks compared with 0.9% in the placebo arm. However, the MACE reduction appeared early (within the first 6 to 12 months) before substantial weight loss had accumulated, suggesting anti-inflammatory and direct vascular effects of semaglutide beyond adipose mass reduction. [16] The 2023 ACC Expert Consensus Decision Pathway on obesity and CVD risk acknowledges this pleiotropic mechanism and recommends GLP-1 RAs for very-high-risk CVD patients with obesity or overweight. [17]

Antithrombotic Therapy: When Is Current Antiplatelet Treatment Failing?

Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is standard after acute coronary syndrome (ACS) or PCI. The duration and composition of that regimen are the subject of ongoing clinical recalibration.

Recurrent Events on Single Antiplatelet Therapy

Patients who experience a second MI or ACS on aspirin monotherapy after the DAPT window (typically 6 to 12 months post-PCI) have a clear antiplatelet treatment-failure signal. The PEGASUS-TIMI 54 trial (N=21,162) showed ticagrelor 60 mg twice daily plus aspirin reduced MACE by 16% (P=0.004) versus aspirin alone in patients with a prior MI 1 to 3 years earlier, establishing extended DAPT as an evidence-based escalation option. [18]

High On-Treatment Platelet Reactivity

Some patients with recurrent ischemic events demonstrate high on-treatment platelet reactivity (HTPR) despite clopidogrel, typically defined as a P2Y12 reaction unit (PRU) above 208 by VerifyNow assay. Switching from clopidogrel to ticagrelor or prasugrel addresses this pharmacogenomic failure mode. The TRITON-TIMI 38 trial (N=13,608) showed prasugrel reduced MACE by 19% compared with clopidogrel in ACS patients undergoing PCI (P<0.001), with the greatest benefit in those with diabetes or prior stent thrombosis. [19]

A Practical Framework for Identifying Treatment Failure

Clinicians managing established CVD benefit from a structured checklist at each follow-up visit. The points below consolidate the failure signals described above into a single clinical workflow.

Step 1. Lipid review (every 3 months after any dose change; annually when stable)

• LDL-C ≥70 mg/dL on high-intensity statin = add ezetimibe.
• LDL-C ≥70 mg/dL on statin plus ezetimibe = consider PCSK9 inhibitor.
• Triglycerides ≥135 mg/dL on statin = consider icosapent ethyl 4 g daily.

Step 2. Event review

• Any new MI, stroke, hospitalization for ACS, or revascularization on current GDMT = treatment failure. Escalate antiplatelet, lipid, and blood pressure therapy simultaneously.

Step 3. Weight and metabolic review

• BMI ≥27 with established CVD after 6 months of structured lifestyle intervention = consider semaglutide 2.4 mg weekly per SELECT criteria.

Step 4. Heart failure monitoring (if applicable)

• LVEF <40% persisting at 3 months on ACEi/ARB + beta-blocker = add MRA.
• Persistent HFrEF symptoms on all three drug classes = add SGLT2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg).

Step 5. Inflammatory and blood pressure assessment

• hsCRP >2.0 mg/L on statin = address lifestyle, consider colchicine 0.5 mg daily.
• Systolic BP >130 mmHg on two antihypertensives = add a third agent or refer to hypertension specialist.

The ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states directly: "Clinicians should monitor and optimize adherence to GDMT at every patient contact." [20] That instruction applies with even greater force in established CVD, where each missed escalation opportunity translates to measurable additional event risk.

Adherence Failure vs. True Pharmacologic Failure

One of the most common errors in managing established CVD is labeling a patient as pharmacologically treatment-refractory when the actual problem is nonadherence or subtherapeutic dosing. Before escalating therapy, confirm:

• Statin adherence by pill-count or pharmacy refill data (a gap of 20% or more in days covered is clinically significant).
• Antihypertensive adherence by urine drug assay when blood pressure remains unexpectedly uncontrolled.
• That the patient is on the correct dose rather than a lower-than-prescribed dose after a side-effect discussion that was not documented.

The EUROASPIRE V survey found that only 56% of coronary patients in secondary prevention were taking statins at the high-intensity doses recommended by guidelines, and only 29% had achieved an LDL-C below 70 mg/dL. [4] That data point means that for many patients the label of "treatment failure" actually reflects a prescribing gap or adherence gap rather than a true refractory state.

When adherence is confirmed and targets remain unmet, escalation is appropriate and guideline-supported.

When to Refer and When to Escalate to Specialist Care

Certain scenarios exceed routine primary-care or general cardiology management:

• Familial hypercholesterolemia (FH) diagnosed by Dutch Lipid Clinic Network score ≥6: refer to a lipid specialist. PCSK9 inhibitors are standard of care for FH with established CVD, and some FH patients may qualify for inclisiran 284 mg every 6 months after the first two doses. [2]
• Refractory hypertension (uncontrolled on three agents including a diuretic): refer for renal artery imaging and aldosterone/renin ratio.
• Recurrent ACS within 12 months despite DAPT and statin: refer to interventional cardiology for anatomic reassessment.
• Persistent HFrEF LVEF below 35% on four-drug GDMT: refer for ICD or CRT evaluation per the 2022 AHA/ACC/HFSA guideline Class I recommendations. [10]